All In Biotech

Drug Trial Radar · NCT06649292

SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

An Open, Randomized,Positive Control, Multicenter Phase III Clinical Study of SHR A1904 for Injection Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patients With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 524 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

524

Planned (sponsor's estimate)

Start

Nov 22, 2024

Primary completion

Sep 20, 2027

Study completion Mar 20, 2028

Sponsor

Sponsor type
Industry
First posted
Oct 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study evaluated the overall survival (OS) of SHR-A1904 versus investigator-selected treatment in second-line CLDN18.2-positive advanced GC/GEJC patients

Conditions

  • Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

  • SHR-A1904Drug

    SHR-A1904

  • Paclitaxel, Docetaxel, IrinotecanDrug

    Paclitaxel, Docetaxel, Irinotecan

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: Until death, assessed up to approximately 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.